Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07526974 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
A Phase 3 study, sponsored by Caliway Biopharmaceuticals Co..
- Not yet
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
NCT07526974 is a Phase 3 study that has not yet begun recruiting, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 320 participants.
The verdict
NCT07526974, a Phase 3 study, has not yet begun recruiting, sponsored by Caliway Biopharmaceuticals Co..
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
Study Summary
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Interventions
- DRUG 0.9% Sodium Chloride
- DRUG CBL-514 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2026-10 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07526974
The ClinicalTrials.gov registry entry for NCT07526974 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caliway Biopharmaceuticals Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.9% Sodium Chloride is the first listed.
NCT07526974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07526974 about?
NCT07526974 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )". A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
What is the current status of trial NCT07526974?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2026-10. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07526974?
The interventions under investigation include: 0.9% Sodium Chloride (DRUG), CBL-514 Injection (DRUG).
Who is sponsoring clinical trial NCT07526974?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.